Clearside Biomedical Inc (NASDAQ: CLSD) started the day on Thursday, with a price decrease of -7.90% at $0.54, before settling in for the price of $0.58 at the close. Taking a more long-term approach, CLSD posted a 52-week range of $0.29-$1.65.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare sector firm’s twelve-monthly sales growth has been 10.40% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was 10.40%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 32.52%. This publicly-traded company’s shares outstanding now amounts to $77.27 million, simultaneously with a float of $61.36 million. The organization now has a market capitalization sitting at $41.87 million. At the time of writing, stock’s 50-day Moving Average stood at $0.7774, while the 200-day Moving Average is $0.9343.
Clearside Biomedical Inc (CLSD) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Clearside Biomedical Inc’s current insider ownership accounts for 21.04%, in contrast to 13.71% institutional ownership. According to the most recent insider trade that took place on Feb 24 ’25, this organization’s Director bought 15,000 shares at the rate of 0.92, making the entire transaction reach 13,800 in total value, affecting insider ownership by 176,141. Preceding that transaction, on Nov 01 ’24, Company’s Chief Medical Officer bought 36,500 for 1.00, making the whole transaction’s value amount to 36,500. This particular insider is now the holder of 100,000 in total.
Clearside Biomedical Inc (CLSD) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.09 per share during the current fiscal year.
Clearside Biomedical Inc’s EPS increase for this current 12-month fiscal period is 32.52% and is forecasted to reach -0.30 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 23.71% through the next 5 years, which can be compared against the 10.40% growth it accomplished over the previous five years trading on the market.
Clearside Biomedical Inc (NASDAQ: CLSD) Trading Performance Indicators
Let’s observe the current performance indicators for Clearside Biomedical Inc (CLSD). It’s Quick Ratio in the last reported quarter now stands at 3.19. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 11.14.
In the same vein, CLSD’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.41, a figure that is expected to reach -0.10 in the next quarter, and analysts are predicting that it will be -0.30 at the market close of one year from today.
Technical Analysis of Clearside Biomedical Inc (CLSD)
If we take a close look at the recent performances of Clearside Biomedical Inc (NASDAQ: CLSD), its last 5-days Average volume was 49.16 million that shows progress from its year to date volume of 2.0 million. During the previous 9 days, stock’s Stochastic %D was recorded 33.58% While, its Average True Range was 40.24%.
Raw Stochastic average of Clearside Biomedical Inc (CLSD) in the period of the previous 100 days is set at 32.35%, which indicates a major fall in contrast to 40.61% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 0.1107 that was higher than 0.0649 volatility it exhibited in the past 100-days period.
